Additionally, the 36-month beta value for CDT is 1.94.
The public float for CDT is 0.74M and currently, short sellers hold a 13.87% ratio of that float. The average trading volume of CDT on June 27, 2025 was 392.20K shares.
CDT) stock’s latest price update
Conduit Pharmaceuticals Inc (NASDAQ: CDT)’s stock price has soared by 15.54 in relation to previous closing price of 2.51. Nevertheless, the company has seen a gain of 26.09% in its stock price over the last five trading days. globenewswire.com reported 2025-06-20 that SHENZHEN, China, June 20, 2025 (GLOBE NEWSWIRE) — CDT Environmental Technology Investment Holdings Limited (NASDAQ:CDTG) (“CDT” or the “Company”), a leading provider of waste treatment systems and services throughout China, today announced that it received a notification letter, dated June 18, 2025 (the “Notification Letter”), from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (“Nasdaq”) indicating that the Company is no longer in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) as the Company’s closing bid price per ordinary share, par value US$0.0025 per share, was below US$1.00 for a period of 30 consecutive business days. The Notification Letter does not result in the immediate delisting of the Company’s securities.
CDT’s Market Performance
Conduit Pharmaceuticals Inc (CDT) has experienced a 26.09% rise in stock performance for the past week, with a -21.41% drop in the past month, and a -74.83% drop in the past quarter. The volatility ratio for the week is 9.22%, and the volatility levels for the past 30 days are at 11.08% for CDT. The simple moving average for the past 20 days is 10.20% for CDT’s stock, with a -96.18% simple moving average for the past 200 days.
CDT Trading at -43.07% from the 50-Day Moving Average
After a stumble in the market that brought CDT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.84% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDT starting from Nirland Ltd, who sale 1,500,000 shares at the price of $0.10 back on Oct 03 ’24. After this action, Nirland Ltd now owns 8,400,000 shares of Conduit Pharmaceuticals Inc, valued at $156,450 using the latest closing price.
Nirland Ltd, the 10% Owner of Conduit Pharmaceuticals Inc, sale 1,368,991 shares at $0.10 during a trade that took place back on Oct 04 ’24, which means that Nirland Ltd is holding 7,031,009 shares at $140,458 based on the most recent closing price.
Stock Fundamentals for CDT
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.65 for the gross margin
The net margin for Conduit Pharmaceuticals Inc stands at 0.02. The total capital return value is set at 0.02. Equity return is now at value -89.65, with -316.98 for asset returns.
Based on Conduit Pharmaceuticals Inc (CDT), the company’s capital structure generated 0.51 points at debt to capital in total, while cash flow to debt ratio is standing at 0.0. The debt to equity ratio resting at 1.04. The interest coverage ratio of the stock is -6.9.
Currently, EBITDA for the company is 266.46 million with net debt to EBITDA at 16.88. When we switch over and look at the enterprise to sales, we see a ratio of 0.48. The receivables turnover for the company is 5.08for trailing twelve months and the total asset turnover is 0.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.31.
Conclusion
In conclusion, Conduit Pharmaceuticals Inc (CDT) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
